妊娠36周筛查后高血压疾病的预测:血管生成标志物与竞争风险模型的比较
这项前瞻性观察研究在妊娠35+0至36+6周比较了低胎盘生长因子、高可溶性fms样酪氨酸激酶-1/胎盘生长因子比值与竞争风险模型对子痫前期分娩的预测性能。在34782例妊娠中,竞争风险模型三联试验对筛查后1周内、2周内及任意时间子痫前期分娩的检出率均高于单一标志物,差异有统计学意义。
要点
- 竞争风险模型三联试验筛查后任意时间子痫前期分娩检出率68%,高于低PlGF的47%和高sFlt-1/PlGF比值的55%。
- 三联试验对筛查后1周内子痫前期分娩检出率91%,高于低PlGF的77%和高sFlt-1/PlGF比值的85%。
- 双联试验在筛查后2周内和任意时间子痫前期预测中优于sFlt-1/PlGF比值,但在1周内未显示优势。
核心结论
- 在妊娠35+0至36+6周,竞争风险模型三联试验对筛查后1周内、2周内及任意时间子痫前期分娩的筛查性能优于单独PlGF或sFlt-1/PlGF比值。
研究设计与样本
- 前瞻性观察研究,纳入2016年至2022年在英格兰两家产科医院于妊娠35+0至36+6周进行常规医院访视的孕妇,共34782例妊娠。
主要发现
- 831例(2.4%)发生子痫前期。
- 筛查后任意时间子痫前期分娩检出率(假阳性率10%):低PlGF为47%,单联试验为54%,高sFlt-1/PlGF比值为55%,双联试验为61%,三联试验为68%。
- 筛查后2周内子痫前期分娩检出率:低PlGF为67%,单联试验为74%,高sFlt-1/PlGF比值为74%,双联试验为80%,三联试验为87%。
- 筛查后1周内子痫前期分娩检出率:低PlGF为77%,单联试验为81%,高sFlt-1/PlGF比值为85%,双联试验为88%,三联试验为91%。
- 任意时间子痫前期预测中,三联试验检出率显著高于单独PlGF(差值20.1%,95%CI 16.7-23.0%)和sFlt-1/PlGF比值(差值12.4%,95%CI 9.7-15.3%);2周内预测差值分别为20.6%(95%CI 14.9-26.8%)和12.9%(95%CI 7.7-17.5%);1周内预测差值分别为13.5%(95%CI 5.4-21.6%)和5.4%(95%CI 0.0-10.8%)。
关键数值与推荐
- 子痫前期定义采用美国妇产科医师学会2019年标准。
- 低PlGF定义为低于第10百分位,高sFlt-1/PlGF比值定义为高于第90百分位。
- 竞争风险模型风险截断值对应10%的筛查阳性率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the performance at 35 + 0 to 36 + 6 weeks' gestation of screening for delivery with pre-eclampsia (PE) at various timepoints, using one of three approaches: placental growth factor (PlGF) concentration, soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF concentration ratio, or the competing-risks model, which combines maternal risk factors with biomarkers to estimate patient-specific risk. METHODS: This was a prospective observational study of women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation at one of two maternity hospitals in England between 2016 and 2022. During the visit, maternal demographic characteristics and medical history were recorded and serum PlGF, serum sFlt-1 and mean arterial pressure (MAP) were measured. Detection rates (DRs) were evaluated for delivery with PE (defined as per American College of Obstetricians and Gynecologists 2019 criteria) within 1 week, within 2 weeks or at any time after screening, using the following strategies: (i) low PlGF (< 10th percentile); (ii) high sFlt-1/PlGF ratio (> 90th percentile); or (iii) the competing-risks model, in which maternal factors were combined with multiples of the median values of PlGF ('single test'), PlGF and sFlt-1 ('double test') or PlGF, sFlt-1 and MAP ('triple test'). Risk cut-offs corresponded to a screen-positive rate of 10%. DRs were compared between tests. RESULTS: Of 34 782 pregnancies, 831 (2.4%) developed PE. In screening for delivery with PE at any time from assessment, the DR at 10% screen-positive rate was 47% by low PlGF alone, 54% by the single test, 55% by high sFlt-1/PlGF ratio, 61% by the double test and 68% by the triple test. In screening for delivery with PE within 2 weeks from assessment, the respective values were 67%, 74%, 74%, 80% and 87%. In screening for delivery with PE within 1 week from assessment, the respective values were 77%, 81%, 85%, 88% and 91%. For prediction of PE at any time, the DR was significantly higher with the triple test compared to PlGF alone or the sFlt-1/PlGF ratio, with a DR difference (95% CI) of 20.1% (16.7-23.0%) and 12.4% (9.7-15.3%), respectively. Similar results were seen for prediction of PE within 2 weeks (20.6% (14.9-26.8%) and 12.9% (7.7-17.5%), respectively) and prediction of PE within 1 week (13.5% (5.4-21.6%) and 5.4% (0.0-10.8%), respectively). The double test was superior to the sFlt-1/PlGF ratio and the single test was superior to PlGF alone in the prediction of PE within 2 weeks and at any time from assessment, but not within 1 week of assessment. CONCLUSION: At 35 + 0 to 36 + 6 weeks' gestation, the performance of screening for PE by the competing-risks model triple test is superior to that of PlGF alone or the sFlt-1/PlGF ratio for the development of disease within 1 week, within 2 weeks and at any time from screening. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Schiattarella A, Magee LA, Wright A, et al. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model. Ultrasound Obstet Gynecol. 2023. PMID: 37329494. doi:10.1002/uog.26291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。